Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

West Pharmaceutical Services, Inc. Common Stock (NY:WST)

372.64 +7.66 (+2.10%)
Delayed Quote Updated: 12:03 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about West Pharmaceutical Services, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
Topics Economy Firearms
News headline image
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Economy
News headline image
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Economy Stocks
News headline image
1 Surging Stock with Solid Fundamentals and 2 That Underwhelm
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
Topics Economy
News headline image
3 Profitable Stocks with Warning Signs
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Economy Supply Chain
News headline image
1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Ignore
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
Topics Economy
News headline image
1 Mid-Cap Stock on Our Buy List and 2 Facing Headwinds
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco... 
Via StockStory
Topics Economy
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
Topics Economy
News headline image
3 Cash-Heavy Stocks We Approach with Caution
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
Topics Economy
News headline image
3 Reasons to Avoid WST and 1 Stock to Buy Instead
West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. T... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call
West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response re... 
Via StockStory
Topics Earnings
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC... 
Via StockStory
News headline image
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.... 
Via StockStory
News headline image
West Pharmaceutical Services Q2 Earnings Call Highlights ↗
West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call ↗
West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8%... 
Via StockStory
Topics Economy
News headline image
West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect. W... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons WST is Risky and 1 Stock to Buy Instead
Over the past six months, West Pharmaceutical Services has been a great trade, beating the S&P 500 by 21.8%. Its stock price has climbed to $353.68, represen... 
Via StockStory
Topics Stocks
News headline image
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
1 High-Flying Stock Worth Your Attention and 2 Facing Challenges
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
Topics Economy
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Economy
Top S&P500 movers in Tuesday's session ↗
Via Chartmill
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Q1 Rundown: UFP Technologies (NASDAQ:UFPT) Vs Other Drug Development Inputs & Services Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including UFP Technologies (NASDAQ:UFPT)... 
Via StockStory
News headline image
3 Profitable Stocks with Open Questions
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Topics Economy
News headline image
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion ↗
The Microsoft founder's foundation recently added this healthcare stock to its portfolio. 
Via The Motley Fool
News headline image
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and i... 
Via StockStory
Topics Artificial Intelligence Economy
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.